Abstract
Management of chronic hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD) is complicated by drug-related toxicity and interactions [1,2]. Dual antiviral therapy with pegylated interferon (Peg-IFN) and ribavirin (RBV) reached sustained virological response (SVR) rates of only ∼30% [1,2]. With the approval of the NS3/NS4a protease inhibitors (PI) telaprevir (TVR) and boceprevir (BOC), PI-based triple therapy as the new standard for antiviral therapy in non-haemodialysis (HD) HCV genotype 1 cohorts leads to significantly higher SVR rates of 66% and 75% in treatment-naive patients [3,4].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
